EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

SGLT-2 inhibition by empagliflozin has no effect on experimental arterial thrombosis in a murine model of low-grade inflammation

Luca Liberale, Simon Kraler iD, Yustina M Puspitasari, Nicole R Bonetti, Alexander Akhmedov iD, Stefano Ministrini, Fabrizio Montecucco iD, Nikolaus Marx iD, Michael Lehrke, Niels-Ulrik K Hartmann, Jürg H Beer, Florian A Wenzl iD und 3 weitere

Cardiovascular Research · 2023

DOI: 10.1093/cvr/cvac126 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cardiovascular Research, 2023. Verfasst von Luca Liberale und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, 8952 Schlieren, Switzerland. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Thrombosis, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Swiss National Science Foundation, Swiss Heart Foundation, Faculty of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Low-grade inflammation couples dysmetabolic states to insulin resistance and atherosclerotic cardiovascular (CV) disease (ASCVD). Selective sodium–glucose co-transporter 2 (SGLT-2) inhibition by empagliflozin improves clinical outcomes in patients with ASCVD independently of its glucose lowering effects. Yet, its mechanism of action remains largely undetermined. Here, we aimed to test whether empagliflozin affects arterial thrombus formation in baseline (BSL) conditions or low-grade inflammatory states, a systemic milieu shared among patients with ASCVD. Methods and results Sixteen-week-old C57BL/6 mice were randomly assigned to acute administration of empagliflozin (25 mg/kg body weight) or vehicle, of which a subgroup was pre-treated biweekly over 4 weeks with super-low-dose lipopolysaccharide (LPS; 5 ng/kg body weight), before carotid thrombosis was induced by photochemical injury. The between-group difference in Doppler-flow probe detected time-to-occlusion remained within the predefined equivalence margin (Δ = |10.50|), irrespective of low-grade inflammation (95% confidence interval, –9.82 to 8.85 and –9.20 to 9.69), while glucose dropped by 1.64 and 4.84 mmoL/L, respectively. Ex vivo platelet aggregometry suggested similar activation status, corroborated by unchanged circulating platelet-factor 4 plasma levels. In concert, carotid PAI-1 expression and tissue factor (TF) activity remained unaltered upon SGLT-2 inhibition, and no difference in plasma D-dimer levels was detected, suggesting comparable coagulation cascade activation and fibrinolytic activity. In human aortic endothelial cells pre-treated with LPS, empagliflozin neither changed TF activity nor PAI-1 expression. Accordingly, among patients with established ASCVD or at high CV risk randomized to a daily dose of 10 mg empagliflozin signatures of thrombotic (i.e. TF) and fibrinolytic activity (i.e. PAI-1) remained unchanged, while plasma glucose declined significantly during 3 months of follow-up.

Conclusion

SGLT-2 inhibition by empagliflozin does not impact experimental arterial thrombus formation, neither under BSL conditions nor during sustained low-grade inflammation, and has no impact on proxies of thrombotic/fibrinolytic activity in patients with ASCVD. The beneficial pleiotropic effects of empagliflozin are likely independent of pathways mediating arterial thrombosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsThrombosisDiabetes Mellitus, Type 2HumansMiceAnimalsDisease Models, AnimalEndothelial CellsSodium-Glucose Transporter 2LipopolysaccharidesPlasminogen Activator Inhibitor 1Mice, Inbred C57BLGlucoseInflammationBody WeightBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

Arterial thrombosisCardiovascular diseaseEmpagliflozinPAI-1SGLT-2 inhibitorsTissue factor

Substanzen

Sodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transporter 2LipopolysaccharidesPlasminogen Activator Inhibitor 1GlucoseempagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, 8952 Schlieren, Switzerland.
  • First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy.
  • University Heart Center, Department of Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Internal Medicine, Angiology and Atherosclerosis, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.
  • IRCCS Ospedale Policlinico San Martino Genoa - Italian Cardiovascular Network, 16132 Genoa, Italy.
  • Department of Internal Medicine I, University Hospital Aachen, RWTH, 52074 Aachen, Germany.

ORCID-Profile: Simon Kraler, Alexander Akhmedov, Fabrizio Montecucco, Nikolaus Marx, Florian A Wenzl, Francesco Paneni, Giovanni G Camici

Förderung

  • Swiss National Science Foundation
  • Swiss Heart Foundation
  • Faculty of Medicine
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Liberale, L., Kraler, S., Puspitasari, Y. M., Bonetti, N. R., Akhmedov, A., Ministrini, S., Montecucco, F., Marx, N., Lehrke, M., Hartmann, N. K., Beer, J. H., Wenzl, F. A., Paneni, F., Lüscher, T. F., & Camici, G. G. (2023). SGLT-2 inhibition by empagliflozin has no effect on experimental arterial thrombosis in a murine model of low-grade inflammation. Cardiovascular Research. https://doi.org/10.1093/cvr/cvac126

Vancouver

Liberale L, Kraler S, Puspitasari YM, Bonetti NR, Akhmedov A, Ministrini S, et al. SGLT-2 inhibition by empagliflozin has no effect on experimental arterial thrombosis in a murine model of low-grade inflammation. Cardiovascular Research. 2023. doi:10.1093/cvr/cvac126

BibTeX
@article{Liberale2023,
  author = {Liberale, Luca and Kraler, Simon and Puspitasari, Yustina M and Bonetti, Nicole R and Akhmedov, Alexander and Ministrini, Stefano and Montecucco, Fabrizio and Marx, Nikolaus and Lehrke, Michael and Hartmann, Niels-Ulrik K and Beer, Jürg H and Wenzl, Florian A and Paneni, Francesco and Lüscher, Thomas F and Camici, Giovanni G},
  title = {SGLT-2 inhibition by empagliflozin has no effect on experimental arterial thrombosis in a murine model of low-grade inflammation},
  journal = {Cardiovascular Research},
  year = {2023},
  doi = {10.1093/cvr/cvac126}
}
Kostenlos starten →